Hormone therapy protects from diabetes: the Kuopio Osteoporosis Risk Factor and Prevention Study

Kati Pentti, Marjo T. Tuppurainen, Risto Honkanen, Lorenzo Sandini, Heikki Kröger, Esko Alhava and Seppo Saarikoski

Kuopio University Hospital, Department of Obstetrics and Gynecology, Kuopio, Finland (Kati Pentti MD; Professor Marjo T. Tuppurainen MD, PhD; Professor Emeritus Seppo Saarikoski MD, PhD)

Kuopio University Hospital, Department of Internal Medicine, Kuopio, Finland (Lorenzo Sandini MD)

Kuopio University, Bone and Cartilage Research Unit, Kuopio, Finland (Professor Marjo T. Tuppurainen MD, PhD; Lorenzo Sandini MD; Risto Honkanen MD, PhD; Professor Heikki Kröger MD, PhD)

Kuopio University Hospital, Department of Orthopaedics, Traumatology and Hand Surgery, Kuopio, Finland (Professor Heikki Kröger MD, PhD)

Institute of Clinical Medicine, Department of Surgery, University of Kuopio, Kuopio, Finland (Professor Esko Alhava, MD, PhD)

Research Institute of Public Health, University of Kuopio (Risto Honkanen MD, PhD)

Address correspondence and reprint requests to:

Kati Pentti, MD
Kuopio University Hospital, Department of Obstetrics and Gynecology
FIN-70211 KUOPIO, Finland
Email: kati.pentti@fimnet.fi
Abbreviations: HT, hormone therapy; OSTPRE, Kuopio Osteoporosis Risk Factor and Prevention Study; DM1 and IDDM, Insulin dependent diabetes; DM2 and NIDDM: non-insulin dependent diabetes; CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction; WHO, World Health Organization; ICD, The International Classification of Diseases; WHI, The Women’s Health Initiative; SII: The Finnish Social Insurance Institution ; MI: Myocardial Infarction; LDL-C: low-density-lipoprotein-cholesterol; HDL-C: high-density-lipoprotein-cholesterol; RR: Relative Risk; HR: Hazard Risk; CI: Confidence Interval; CEE: conjugated equine estrogens; MPA: medroxyprogesterone
Abstract

Objectives: The purpose of this population-based prospective cohort study was to examine the effect of hormone therapy (HT) on incidence of diabetes (DM).

Design and Methods: 8483 DM free postmenopausal women aged 52-62 from the population-based OSTPRE-study were followed for 5 years in 1994-1999. Information about use of HT and health events was obtained from three repeated questionnaires in 1989, 1994 and 1999. DM morbidity before and during the follow-up was obtained from the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII). Kaplan-Meier survival curves and Cox’s proportional-hazards models were used to estimate the risk of incident DM in relation to the use of HT.

Results: During the follow-up, 40.8 % DM free postmenopausal women had never used HT, 27.3 % women were HT past users and 31.9 % women had used HT currently during the follow-up. During the follow-up 162 incident DM cases were recorded. Compared with never users of HT, the adjusted hazard ratio (HR) of DM was 0.81 (95% confidence interval (CI) 0.57 to 1.16) for only in the past users, 0.53 (95% CI 0.24 to 1.15) in part-time (during the follow-up < 2.5 years) users and 0.31 (95% CI 0.16 to 0.60) in continuous (during the follow-up 2.5-5.0 years) users of HT.

Conclusions: HT use decreases the incidence of diabetes in postmenopausal women.
Key words: Diabetes, Morbidity, HT, Postmenopausal, population-based
INTRODUCTION

Diabetes (DM) is one of the most common chronic diseases in the world. Type 2 diabetes is increasingly being recognized as a critical health problem especially in middle-aged and elderly people (1). Obesity and physical inactivity are established risk factors for type 2 diabetes and cardiovascular comorbidities (2). It is estimated that the number of diabetic people in the world will double from 171 million in 2000 to 366 million in 2030. Globally, the prevalence of diabetes is similar in men and women, but it is slightly higher in men under the age of 60 and in women at older ages. (3)

Recent studies have suggested that postmenopausal HT is associated with lower incidence of DM. The Heart Estrogen Progestin Replacement Study (HERS) (4) and the Women’s Health Initiative (WHI) trials (5, 6) were the first randomized controlled studies showing the positive effects of HT on diabetes. Primarily HERS (4) and the WHI (5, 6) studied the effects of HT on cardiovascular disease and there was no improvement of cardiovascular outcomes but on the contrary a significantly lower incidence of DM among HT users. Some (7) but not all (8, 9) observational studies have also noted a decreased incidence of DM among postmenopausal HT users.

The primary aim of this prospective 5-year study from the population-based study cohort was to examine the effects of HT on the incidence of diabetes in postmenopausal women.
MATERIAL AND METHODS

Study population

This study is a part of the Kuopio Osteoporosis Risk Factor and Prevention (OSTPRE) population-based prospective cohort study. The target population primarily consisted of the 14,220 women resident in Kuopio Province and born in 1932-41 (aged 52-62 years in 1994) to whom a postal inquiry was sent in May 1989. The study population has been described in detail previously (10). In all, 13,100 women (92.8%) responded. The second follow-up inquiry was sent to women alive in May 1994. A total of 11,798 women responded to both inquiries. Women whose hormone therapy (HT) use in May 1994 could not be clarified were excluded (n=131). A woman was regarded as postmenopausal if ≥12 months had elapsed since her last natural menstruation or if she had undergone bilateral oophorectomy before May 1994. A total of 839 premenopausal women and women whose menopause could not be defined due to hysterectomy (n=1146) or to incomplete data (n=328) were also excluded from the study. Women were considered to have previous diabetes (DM) if they self-reported DM, current use of insulin or oral glucose-lowering medications in 1989 or 1994 and women with that information about DM before the start of follow-up according to the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII) (total n=282). There were 9072 postmenopausal non-diabetic women in May 1994. In all 8483 (of 9072) postmenopausal women responded also to the third follow-up inquiry in May 1999 which was forming the final study population of this study.

This study was approved by the local ethics committee in 1986, 1994 and 1997.
HT

The lifetime use of HT in years before the baseline of this study was recorded in two postal enquiries in 1989 and 1994. The duration of HT use in months for each year of follow-up in 1994-9 was recorded by postal enquiry in 1999. Inconsistent or missing HT information was clarified by telephone interview or by additional postal enquiry. HT use was defined as use of preparations having systemic estrogenic properties, and classified in 4 categories as follows: never, only in the past (before baseline 1994), part-time (<2.5 years of HT use during the follow-up) and continuous (2.5-5.0 years of HT use during the follow-up). The uniformity of HT use was examined and was found to be approximately uniform throughout the follow-up.

Diabetes

New cases of established DM during the follow-up (N=162) were ascertained with the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII). According to the National Sickness Insurance, The SII granted 100% reimbursement for drug costs in defined chronic illnesses necessitating continuous medication, like DM.

According to the National Sickness Insurance the criteria for reimbursement of medicines in Diabetes (ICD-9 codes 250.0-250.9 and ICD-10 codes E10-E14, E89.1) are as follows:

Examinations and diagnosis of type 1 diabetes (DM1) and type 2 diabetes (DM2) has to be made in the specialized health care unit or by a specialist physician. Due to high prevalence of DM2, right to reimbursement can be based also upon an opinion from any physician.

I. Patient has the right to reimbursement for DM2 medication when the patient has typical symptoms of DM (polyuria, polydipsia and glucosuria) and fasting glucose in capillary or vein
blood is at least 7.0 mmol/l or in plasma blood at least 8.0 mmol/l. If the symptoms of DM are missing, DM diagnosis has to be confirmed by repeated testing.

II. Patient has the right to reimbursement for DM2 medication when the patient has used DM medication for at least 6 months and the positive effects of medication have been described. An overweight DM2 patient must undergo at least 6 months of dietary treatment before medical treatment. The medical certificate concerning DM2 must include information about the duration of diet use and its effects on weight. Furthermore the symptoms, findings and blood and urine glucose status and possible albuminuria, especially before medical treatment, may be described. When DM diagnosis has been made, a medical doctor will write the statement to the SII, which will then give the patient the right to where reimbursement for DM.(11) In the present study, the date of a physician’s statement for DM was used as the endpoint of DM follow-up. In all, 162 postmenopausal women had new incident DM during the follow-up.

Other variables

The inquiries included questions about gynaecological history (parity, last menstruation and menopausal symptoms) and surgery, height, weight, smoking and chronic health disorders diagnosed by physician (with >100 different items). Current medication prescribed by a doctor was also asked in both inquiries: as well as the names of medications (including duration of use) and diseases that they were taking medications for. SII registry was used together with the inquiries in 1989 and 1994 to determinate the women’s baseline status concerning the occurrence of hypertension and hypercholesterolaemia. Body mass index (BMI) was calculated as the ratio of weight in kilograms to height in square meters (kg/m²).
Statistical analysis

The statistical analyses were performed with the SPSS (INC 14.0) program. The differences in baseline characteristics between HT users (during the follow-up) and never users were tested by using analysis of variance (ANOVA) to compare the means of continuous variables and the x² test to compare categorical variable distributions. P values of less than 0.05 were considered significant. Kaplan–Meier survival curves with the log rank test were used to examine the effect of HT use on the incidence of DM. Kaplan-Meier survival curves were also used for evaluation of the applicability of life table models (which assume constant incidence of endpoint events) on our data. Cox’s proportional-hazard models were used to study the association of HT use with DM incidence after adjustment for covariates. The covariates used age, parity, BMI, hypertension (no, yes), hypercholesterolaemia (no, yes), status of hysterectomy (no, yes) and smoking history (never, ever). Possible interactive effects of HT use and these covariates on the risk of DM were examined using correlation matrices from Cox’s models. Follow-up times were calculated as the time from the 1st of June 1994 to 31st of May 1999 or date of reimbursement decision about DM from SII, whichever came first. P values of less than 0.05 were considered significant.
Results

Past use of HT was reported by 27.3% and current HT use during the follow-up by 31.9% of the 8483 non-diabetic postmenopausal women during the five years follow-up. Mean duration of current HT use during the follow-up was 3.75 years. HT use during follow-up was quite evenly distributed for the 5 years of follow-up. The rest (40.8%) of women had never used HT nor started it during the follow-up. The average follow-up time was 4.96 years (range 0.04 – 5.00). There were some marked differences in baseline characteristics between HT users and non-users (Table 1). Women who used HT during the follow-up HT were slightly younger, had a lower BMI and had fewer children than non-users. HT users during the follow-up reported slightly less hypertension than never users. Women who used HT only in the past more often had hypertension than never users. HT users had undergone more hysterectomies than never users. (Table 1).

During the follow-up there were 162 new DM events occurred (n=8483). The incidence of the DM remained constant throughout the follow-up. Overall, 90 DM incidents were found in HT never users, 51 DM incidents in only past HT users, 8 DM incidents in part-time (<2.5 years) HT users and 13 DM incidents in continuous (2.5-5.0 years) HT users in the whole cohort. (Table 2 and figure 1) The DM incidence was 3.85 per 1000 person-years in the whole cohort, 5.26 per 1000 person-years, in HT never users, 4.45 per 1000 person-years in only the past users, 2.34 per 1000 person-years in part-time (<2.5 years) HT users and 1.29 per 1000 person-years in continuous (2.5-5.0 years) HT users, respectively.
The use of HT was associated with a decreased risk of DM in the postmenopausal women. In the multivariate Cox regression analysis, the risk of DM as hazard ratio (HR) was 0.81 (95% Confidence Interval (CI) 0.57 to 1.16) in only past HT users, 0.53 (95% CI 0.24 to 1.15) in women who used HT part-time (<2.5 years) during the follow-up and 0.31 (95% CI 0.16 to 0.60) in women who used HT continuous (2.5-5.0 years) during the follow-up compared with HT never users (Table 2). None of the covariates interacted with HT use.
Discussion

In the present population-based 5-year prospective cohort study on postmenopausal women HT use significantly decreased the risk of developing DM. The risk decrease was accentuated (69%) in women who used HT more than half of the follow-up time.

The strengths of this study include its population-based nature, detailed information about HT use and careful diagnosis of incident IDDM based on the registry of specially refunded drugs of the Finnish Social Insurance Institution (SII). The registries in Finland have proven to be reliable. (12) A limitation of our study was that baseline characteristics of current HT users had fewer risk factors than HT nonusers. However, adjusting for those characteristics did not affect the results. In addition no interactions between HT use and these factors were found. Our study did not distinguish between unopposed oestrogen and combined therapy or between oral and transdermal application.

Several observational studies and RCTs have examined the role of HT use in the prevention of diabetes but none of those studies has found as strong of a preventive effect as this study (4-7). Manson et al (7) reported a 20 % lower incidence of DM in women using HT compared to women who did not use it in the Nurse’s Health Study. In a randomised controlled trial, the HERS study (4), the corresponding decrement was 35%. Lastly, the WHI trial reported 11-17 % lowered risk of DM in HT users compared with nonusers (5, 6). On the other hand, the Strong Heart Study (8) reported that the risk of type 2 DM increased by 10% per year of current oestrogen use, while Gabal et al (9) did not find a statistically significant change in DM risk related to HT use.
Unlike these studies, in our present study in postmenopausal women DM risk reduction related to current HT use during the follow-up was remarkable (62% for all current HT users during the follow-up) compared with never users. The great majority of the women, who used HT during follow-up of our study had started HT before baseline. This long-term HT exposure may partly explain the results of our study. Women who have used HT only in the past and may have stopped the use of HT before the follow-up may have lost part of its benefit, whereas women who have started HT use only a short time ago may not have yet reached the full benefit of it. Finnish women with an intact uterus mainly use oestradiol combined with norethisterone acetate or levonorgesterel. Finnish women who have undergone hysterectomy use mainly oestradiol only.

During menopause, women gain body fat in the abdominal region, and insulin sensitivity decreases (13, 14). These changes, along with dyslipidemia and hypertension, are consistent with the metabolic syndrome and predict DM2 (15) and CHD (16) in postmenopausal women. HT can have favourable effects on body fat distribution and could, therefore, act to reduce diabetes risk via this mechanism (17).

Several studies indicate that oestrogen therapy may attenuate the accumulation of central fat in postmenopausal women (18-21). In the PEPI trial (22), less weight gain or increase in waist and hip circumferences were registered in women who received E+P therapy compared to placebo. Similarly, in the Danish Osteoporosis Prevention Study (DOPS) (23), HT use seemed to have a weight-reducing effect.
There are several mechanisms other than effects on adiposity tissue and body fat distribution by which HT may be protective against DM. In a prospective study of older women not using HT, endogenous levels of bioavailable estradiol and testosterone were positively associated with levels of fasting glucose, insulin and estimated insulin resistance, whereas only bioavailable testosterone predicted incident diabetes (24). Positive associations of bioavailable estradiol and testosterone with insulin resistance have also been observed in a cross-sectional study of untreated postmenopausal women (25). Low levels of sex hormone binding globulin (SHBG) are related negatively with obesity, insulin resistance and incidence of diabetes in postmenopausal women (26-28). Hyperandrogenicity in women is closely associated with insulin resistance and risk factors for cardiovascular disease and type 2 DM.

It has been hypothesised that oestrogen may also have direct effect on secretion of insulin by the pancreas. For example, oestrogen receptors are present in pancreatic beta cells (29), and oestrogen increases the release of insulin in beta cell culture models (30).

In conclusion, the present prospective cohort study indicates that HT use reduces the risk of diabetes in postmenopausal women. Further information on the role of HT, according to the route of administration and dose in modifying the risk of diabetes is needed.
Disclosure

Conflict of interest statement: None declared

Acknowledgements

Funding Sources

The authors would like to thank Kuopio University Hospital (EVO-grant), the Finnish Menopause Society (grant), the Academy of Finland (grant), National Statistics Finland, and the Finnish Social Insurance Institution for support of this work.
References


11 The Finnish Social Insurance Institution (Kela)


14 Wu SI, Chou P & Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. *Journal of clinical epidemiology* 2001 **54** 117-120.


19 Sorensen MB, Rosenfalck AM, Hojgaard L & Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. *Obesity research* 2001 **9** 622-626.


26 Haffner SM, Dunn JF & Katz MS. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. *Metabolism: clinical and experimental* 1992 **41** 278-284.


29 Sutter-Dub MT. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. *Steroids* 2002 **67** 77-93.


**Figure Legend**

Figure 1. Remaining free of diabetes according to the HT use (Kaplan – Meier survival curves). (Log rank p<0.001).
Use of HT
- + continuous (≥2.5 years)
- * part-time (<2.5 years)
- Past
- ▲ Never

Figure 1.
Table 1 BASELINE CHARACTERISTICS (in 1994) OF THE 8483 NON-DIABETIC POSTMENOPAUSAL WOMEN ACCORDING TO THE HT USE

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>NEVER (N, %)</th>
<th>PAST (N, %)</th>
<th>CURRENT (N, %)</th>
<th>TOTAL (N)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%)</td>
<td>3463 (40.8%)</td>
<td>2314 (27.3%)</td>
<td>2706 (31.9%)</td>
<td>8483</td>
<td></td>
</tr>
<tr>
<td>Age (mean, (S.D.))</td>
<td>58.1 (2.8)</td>
<td>57.7 (2.8)</td>
<td>56.6 (2.7)</td>
<td>57.6 (2.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m², mean (S.D.))</td>
<td>27.5 (4.7)</td>
<td>26.3 (4.3)</td>
<td>26.3 (4.0)</td>
<td>25.7 (3.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Parity (mean, (S.D.))</td>
<td>2.6 (1.7)</td>
<td>2.5 (1.6)</td>
<td>2.3 (1.4)</td>
<td>2.5 (1.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>18.5</td>
<td>19.5</td>
<td>19.1</td>
<td>18.9</td>
<td>0.608</td>
</tr>
<tr>
<td>Chronic hypercholesterolemia (%)</td>
<td>16.6</td>
<td>18.2</td>
<td>15.0</td>
<td>16.5</td>
<td>0.010</td>
</tr>
<tr>
<td>Chronic hypertension (%)</td>
<td>24.9</td>
<td>28.2†</td>
<td>22.1†</td>
<td>24.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hysterectomy (%)</td>
<td>6.5</td>
<td>11.6†</td>
<td>20.0†</td>
<td>12.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Comparison of each HT group with non-users by 1994, †P < 0.05, X² test, ¶P < 0.05, ANOVA.
*during follow-up
### Table 2
The relative risk of incident diabetes (DM) as hazard ratios (HR with 95% CI) in relation to use of HT in postmenopausal women during the 5-year follow-up

<table>
<thead>
<tr>
<th>Use of HT</th>
<th>DM (N=162)</th>
<th>Age-adjusted</th>
<th>Multivariate(95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>90</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Past</td>
<td>51</td>
<td>0.86 (0.61 - 1.21)</td>
<td>0.81 (0.57 - 1.16)</td>
</tr>
<tr>
<td>Part-time (&lt;2.5 years)</td>
<td>8</td>
<td>0.46 (0.22 - 0.94)</td>
<td>0.53 (0.24 - 1.15)</td>
</tr>
<tr>
<td>Continuous (≥2.5 years)</td>
<td>13</td>
<td>0.26 (0.15 - 0.47)</td>
<td>0.31 (0.16 - 0.60)</td>
</tr>
</tbody>
</table>

Multivariate covariates: age, bmi (kg/m²), parity, hypertension (n/y), hypercholesterolemia (n/y), hysterectomy (n/y) and smoking (never, ever)